Here’s Why BioXcel Therapeutics Stock Got Hammered This Week

What happened
Shares of BioXcel Therapeutics(NASDAQ:BTAI), a clinical-stage biotechnology company, fell hard this week as shareholders responded to a secondary share offering. Since the market closed last Friday, the biotech stock has lost around 16.8%…

Click here to view the original article.